Literature DB >> 28969884

Prognostic factors in head and neck mucoepidermoid carcinoma: experience at a single institution based on 64 consecutive patients over a 28-year period.

M Granic1, P Suton2, D Mueller3, I Cvrljevic4, I Luksic5.   

Abstract

Mucoepidermoid carcinoma (MEC) is the most common malignancy of the salivary glands. The clinical behaviour of MEC is largely unpredictable, ranging from indolent tumour growth to highly aggressive metastatic spread. The objective of this study was to determine the clinicopathological predictors of recurrence and survival in patients with head and neck MEC. The medical records of 64 patients who underwent surgical treatment for head and neck MEC between 1982 and 2010 were reviewed. The main outcome measures were disease-free survival (DFS) and overall survival (OS). Clinicopathological parameters evaluated were age, sex, anatomical subsite, histological grade, tumour stage, tumour size, adjuvant therapy, and nodal and margin status. For the entire cohort, the 5-year DFS was 82.8% and the 5-year OS was 67.2%. Histological grade and tumour subsite were statistically significant predictors of OS. Furthermore, tumour stage and nodal status were statistically significant predictors with respect to OS. Advanced tumour stage, high histological grade, submandibular/sublingual localization, and positive nodal status were independent predictors of the prognosis in patients with head and neck MEC. Further studies into the molecular biology of MEC are needed in order to provide new therapeutic strategies for patients with locally aggressive and highly metastatic carcinomas.
Copyright © 2017 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  head and neck; mucoepidermoid carcinoma; recurrence; salivary gland tumours; survival

Mesh:

Year:  2017        PMID: 28969884     DOI: 10.1016/j.ijom.2017.09.005

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  5 in total

1.  Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma.

Authors:  Renata L Markman; Liana P Webber; Carlos H V Nascimento Filho; Leonardo A Reis; Pablo A Vargas; Marcio A Lopes; Virgilio Zanella; Manoela D Martins; Cristiane H Squarize; Rogerio M Castilho
Journal:  Cell Oncol (Dordr)       Date:  2018-12-11       Impact factor: 6.730

2.  Mucoepidermoid carcinoma: Evaluating the prognostic impact of primary tumor site.

Authors:  Ximena Mimica; Avery Yuan; Ashley Hay; Nora Katabi; Daniella Karassawa Zanoni; Cristina Valero; Jatin P Shah; Richard J Wong; Marc A Cohen; Snehal G Patel; Ian Ganly
Journal:  Oral Oncol       Date:  2021-11-09       Impact factor: 5.337

3.  Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients with Major Salivary Gland Mucoepidermoid Carcinoma.

Authors:  Jia-Qian Hu; Peng-Cheng Yu; Xiao Shi; Wan-Lin Liu; Ting-Ting Zhang; Bo-Wen Lei; Nai-Si Huang; Wei-Bo Xu; Li-Tao Han; Ben Ma; Tian Liao; Wen-Jun Wei; Yu Wang; Zhong-Wu Lu; Yu-Long Wang; Qing-Hai Ji
Journal:  J Cancer       Date:  2019-07-22       Impact factor: 4.207

4.  Postoperative radiotherapy for thymus salivary gland carcinoma: A case report.

Authors:  Rui Deng; Nan-Jing Li; Liang-Liang Bai; Shi-Hong Nie; Xiao-Wen Sun; Yong-Sheng Wang
Journal:  World J Clin Cases       Date:  2022-09-16       Impact factor: 1.534

Review 5.  Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review.

Authors:  Giuditta Mannelli; Lara V Comini; Andrea Sacchetto; Roberto Santoro; Giuseppe Spinelli; Pierluigi Bonomo; Isacco Desideri; Paolo Bossi; Ester Orlandi; Giammarco Alderotti; Alessandro Franchi; Annarita Palomba; Albino Eccher; Daniele Marchioni; Riccardo Nocini; Cesare Piazza; Gabriele Molteni
Journal:  Head Neck       Date:  2022-04-20       Impact factor: 3.821

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.